Dear Pharmaceutical Professional,
The renal cell carcinoma market will be impacted by data presented during the virtual American Society of Clinical Oncology (ASCO) GU meeting.
As seasoned experts in bringing congress data to oncologists in their practice, our team will be working with 30 academic and community oncologists during the meeting to better understand the commercial implications of data presented for:
- axitinib
- cabozantinib
- PD-1/PD-L1 inhibitors: nivo, pembro avelumab (in combination with TKI – axitinib, cabozantinib)
Order your 60-slide report so you can make better decisions today and prepare for tomorrow.
Sincerely,
The Breaking Data Team
